NORTH CHICAGO, Ill. , May 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time .

NORTH CHICAGO, Ill. , April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2016 Global Health Care Conference on Thursday, May 12, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer

- Reports First-Quarter Adjusted Diluted EPS of $1.15, Up 22.3 Percent; GAAP Diluted EPS of $0.83 - Delivers First-Quarter Net Revenues of $5.96 Billion, an Increase of 22.4 Percent Over First-Quarter 2015 on an Operational Basis; Reported Net Revenues Increased 18.2 Percent - Delivers Adjusted

- Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug conjugate targeting cancer stem cell protein DLL3 - Compelling data on Rova-T was presented at the European Society of Medical Oncology demonstrating overall response rates of 44 percent in DLL-expressing small cell lung

- Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to License Probody Drug Conjugates for up to Two Additional Undisclosed Targets - CytomX to Receive $30 Million Upfront Payment NORTH CHICAGO, Ill.

NORTH CHICAGO, Ill. and BREDA, The Netherlands and GHENT, Belgium , April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic

NORTH CHICAGO, Ill. , April 20, 2016 /PRNewswire/ --  AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 41 st Annual Health Care Conference on Wednesday, May 4, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at

NORTH CHICAGO, Ill. and INGELHEIM, Germany , March 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis.

NORTH CHICAGO, Ill. , April 7, 2016 /PRNewswire/ --  AbbVie (NYSE: ABBV) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern).

NORTH CHICAGO, Ill. , March 8, 2016 /PRNewswire/ --  AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at 8 a.m.